Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use.

EW BRUNSWICK, N.J., – Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since the month of January 2020; the large expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the fast pace building up of the manufacturing capacity with the plan of providing worldwide distribution of over one billion vaccine doses. They expect to start human clinical studies of this lead vaccine candidate by September of 2020 and foresee the first batches of a COVID-19 vaccine may possibly be available for emergency usage authorization in the beginning of 2021, a much more accelerated time frame compared to the typical vaccine development process.